Close Menu

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Vitro Diagnostics today announced that it has amended an agreement with HemoGenix covering stem cell analysis tools.

The amended agreement expands upon the original agreement to include development of stem cell culture media and high-performance toxicity assays for new cell-based tools for drug discovery and development. The firms also intend to align their respective quality programs to assure consistency, said Golden, Colo.-based Vitro.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A small, early-stage trial of a combination therapy for brain cancer reports favorable responses in two patients, according to the Guardian.

Nature News writes that viral genomic surveillance in the US faces systemic issues.

President Joe Biden is seeking an increase in federal spending, including higher budgets for the National Institutes of Health and Centers for Disease Control and Prevention.

In PLOS this week: sex-stratified genome-wide association study of chronic pain, sequencing data from Indigenous Mexican groups, and more.